Shots:
- Generic medicines are the backbone of the healthcare system and are identical to the innovator medicine in strength- effect- dosage form- and route of administration. These are allowed for sale after the patent expiry of the original drugs
- Our team at PharmaShots has compiled a list of the top 20 generic companies based on their 2020 generic revenue
- In the top 20 ledgers- Sandoz secured the top position with total revenue of $9.46B in the generic segment in 2020
Generic Segment Revenue: $0.22B
Founded Year: 1984
Market Cap: $8.20B
Total Employees: 6-579
Headquarter: Mumbai- India
Stock Exchange: NSE
Piramal Healthcare is one of the leading pharmaceutical companies that deals with producing medicines in therapeutic areas such as diabetes- cardiovascular- inflammation and infectious diseases. In June 2020- Piramal sells 20% in pharmaceutical business to Carlyle for $490 million. Piramal Healthcare has generated revenue of $0.22B in 2020 from its generic segment.
Generic Segment Revenue: $0.31B
Founded Year: 1978
Market Cap: $5.40B
Total Employees: 12-609
Headquarter: Bengaluru- India
Stock Exchange: NSE
Biocon is an Indian Biopharmaceutical company that pivots its attention towards producing innovative drugs in areas such as oncology- immunotherapy and nephrology products. Biocon manufactures generic active pharmaceutical ingredients. In November 2020- Biocon planned a capex of $280 million for generic business over the next three years. In 2020- Biocon has generated revenue of $0.31B from its generic segment.
Generic Segment Revenue: $0.68B
Founded Year: 1867
Market Cap: $0.01B
Total Employees: 3-086
Headquarter: Surrey- United Kingdom
Stock Exchange: OTCMKTS
Mallinckrodt is an American-Irish pharmaceutical company. It targets on producing novel drugs in areas such as neurology- pulmonology- nephrology and rare diseases. In August 2020- Mallinckrodt announced US FDA filing acceptance of Biologics License Application for StrataGraft for the treatment of adults with thermal burns. In 2020- Mallinckrodt generated revenue of $0.68B from its generic segment.
Generic Segment Revenue: $0.78B
Founded Year: 1997
Market Cap: $1.02B
Total Employees: 3-397
Headquarter: Dublin- Ireland
Stock Exchange: NASDAQ
Endo International is a global pharmaceutical company that runs its business across a wide range of therapeutic areas including Endocrinology- Medical Aesthetics- Orthopaedics- and Urology & Men’s Health. In December 2020- Endo completed acquisition of BioSpecifics. Endo has generated revenue of $0.78B from its generic segment in 2020.
Generic Segment Revenue: $1.09B
Founded Year: 1959
Market Cap: $6.29B
Total Employees: 13-801
Headquarter: Ahmedabad- India
Stock Exchange: NSE
Torrent is a leading pharmaceutical company and is ranked 8th in the Indian pharmaceutical market. It spotlights on developing novel therapies of Cardiovascular- central nervous system- gastro-intestinal- oncology- nephrology- anti-infective and pain management segments. Torrent Pharma is ranked 11th among Indian companies operating in the US generic market. Torrent has generated business of $1.09B from its generic segment.
Generic Segment Revenue: $1.13B
Founded Year: 1973
Market Cap: $125.95B
Total Employees: 99-412
Headquarter: Paris- France
Stock Exchange: EPA
Sanofi is a French multinational pharmaceutical company that covers 7 major therapeutic areas: cardiovascular- central nervous system- diabetes- internal medicine- oncology- thrombosis and vaccines. In September 2020- Sanofi completed Principia Biopharma Inc. Acquisition. In 2020- Sanofi has generated a sale of $1.13B from its generic segment.
Generic Segment Revenue: $1.34B
Founded Year: 2002
Market Cap: $1.67B
Total Employees: 6000
Headquarter: New Jersey- United States
Stock Exchange: NYSE
Amneal is an emerging pharmaceutical company that focuses across a broad range of therapeutic areas including cardiovascular- central nervous system- oncology- inflammation- anti-infective- dermatology- endocrinology- diabetes- and urology. In 2020- Amneal launched generic drugs Fluphenazine and Butrans. Amneal has generated a sale of $1.34B in 2020 from its generic segment.
Generic Segment Revenue: $1.49B
Founded Year: 1977
Market Cap: $1.84B
Total Employees: 14-000
Headquarter: Mumbai- India
Stock Exchange: NSE
Glenmark is an Indian pharmaceutical company that develops novel therapies for areas such as dermatology- respiratory- cardiology- diabetes- oncology and anti-infective. In June 2020- Glenmark became the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir- for the treatment of mild to moderate COVID-19. In December 2020- Glenmark became the first company to launch Remogliflozin and Vildagliptin fixed dose combination- at an affordable price for adults with Type 2 Diabetes in India. In 2020- Glenmark has generated a sale of $1.49B from its generic segment.
Generic Segment Revenue: $1.69B
Founded Year: 1929
Market Cap: $1.96B
Total Employees: 3003
Headquarter: Osaka- Japan
Stock Exchange: TYO
Sawai is a Japan based pharmaceutical company associated with novel drug development in areas such as cardiovascular- diabetes drugs- anticancer drugs- and OTC drugs. In December 2020- Sawai launched two generic drugs with 10 strengths including Pregabalin and Rivastigmine. In 2020- Sawai has reported total sale of $1.69B from its generic segment.
Generic Segment Revenue: $2.01B
Founded Year: 1895
Market Cap: NA
Total Employees: 12-301
Headquarter: Bad Vilbel- Germany
Stock Exchange: NA
Stada is German based pharmaceutical company that mainly focuses on production of generic and over-the-counter drugs. In 2020- Stada acquired Lobsor Pharmaceuticals AB. Stada also acquired the product portfolio of Opti Pharm AG- a Swiss company specializing in the trade and distribution of pharmaceutical products. Stada has generated sales of $2.01B from its generic segment in 2020.
Generic Segment Revenue: $2.11B
Founded Year: 1984
Market Cap: $10.1B
Total Employees: 21-650
Headquarter: Hyderabad- India
Stock Exchange: NSE
Dr.Reddy is an Indian pharmaceutical company that targets on developing novel therapies in areas such as oncology- cardiovascular- diabetes- dermatology- nephrology and urology. In June 2020- Dr. Reddy’s Laboratories completed the acquisition of select business divisions of Wockhardt. In 2020- Dr.Reddy has recorded sales of $2.11B from its generic segment.
Generic Segment Revenue: $2.16B
Founded Year: 1968
Market Cap: $5.63B
Total Employees: 18-302
Headquarter: Mumbai- India
Stock Exchange: NSE
Lupin is an Indian pharmaceutical company that specifically focuses on developing novel drugs in therapeutic areas such as paediatrics- cardiovascular- anti-infectives- diabetology- asthma and anti-tuberculosis. In August 2020- Lupin received approval for generic Albuterol Sulphate MDI. In 2020- Lupin has generated sales of $2.16B from its generic segment.
Generic Segment Revenue: $2.34B
Founded Year: 1978
Market Cap: $7.71B
Total Employees: 8-600
Headquarter: London- United Kingdom
Stock Exchange: LON
Hikma is a British multinational pharmaceutical company that targets its business in key areas such as anti-infectives- cardiovascular- central nervous system- diabetes- oncology- respiratory. In March 2020- Hikma launched Everolimus tablets to expand its generics portfolio. In December 2020- Hikma also launched generic Advair Diskus. In 2020- Hikma has generated revenue of $2.34B from its generic segment.
Generic Segment Revenue: $2.61B
Founded Year: 1935
Market Cap: $9.60B
Total Employees: 25-845
Headquarter: Mumbai- India
Stock Exchange: NSE
Cipla is an Indian pharmaceutical company that develops novel drugs for areas such as respiratory- cardiovascular disease- arthritis- diabetes- weight control and depression. In 2020- Cipla received final approval for generic version of Migranal and Proventil. In 2020- Cipla has generated revenue of $2.61B from its generic segment.
Generic Segment Revenue: $3.38B
Founded Year: 1986
Market Cap: $5.31B
Total Employees: 18-469
Headquarter: Hyderabad- India
Stock Exchange: NSE
Aurobindo Pharma is an Indian pharmaceutical company that is specialised in manufacturing generic pharmaceuticals. Aurobindo focuses on key therapeutic areas including neurosciences- cardiovascular- anti-retrovirals- anti-diabetics- and gastroenterology. Aurobindo is among the top 10 pharmaceutical companies in India. In April 2020- Aurobindo received the final approval from l from the US Food and Drug Administration (USFDA) to manufacture and market Fluoxetine tablets in the strengths of 10 mg and 20 mg. In 2020- Aurobindo has generated sales of $3.38B from its generic segment.
Generic Segment Revenue: $3.58B
Founded Year: 1999
Market Cap: $26.12B
Total Employees: 311-269
Headquarter: Bad Homburg- Germany
Stock Exchange: ETR
Fresenius Kabi is a global healthcare company that focuses on multiple therapeutic areas including oncology- Generic & IV drugs- and Biosimilars- Infusion and Nutrition therapies. In October 2020- Fresenius Kabi launched Diprivan- the company first smart labelled product with Radio Frequency Identification (RFI). In 2020- Fresenius Kabi has generated sales of $3.58B from its generic segment.
Generic Segment Revenue: $4.52B
Founded Year: 1983
Market Cap: $25.89B
Total Employees: 36-000
Headquarter: Mumbai- India
Stock Exchange: NSE
Sun Pharma is an Indian pharmaceutical company that manufactures drugs in multiple therapeutic areas including cardiology- psychiatry- neurology- gastroenterology and diabetology. In August 2020- Sun Pharma launched FluGuard- which is used for the treatment of mild to moderate cases of Covid-19 in India. In 2020- Sun Pharma has generated revenue of $4.52B from its generic segment.
Generic Segment Revenue: $5.28B
Founded Year: 2020
Market Cap: $15.84B
Total Employees: 45-000
Headquarter: Pennsylvania- United States
Stock Exchange: NASDAQ
Viatris is a global healthcare company that specifically targets its business in therapeutic areas such as cardiovascular- oncology- immunology- CNS- infectious disease- gastroenterology- dermatology and respiratory for developing new drug therapies. In November 2020- Mylan merged with Upjohn- Pfizer’s off-patent medicine division- to form Viatris. In 2020- Viatris has recorded sales of $5.28B from its generic segment.
Generic Segment Revenue: $9.31B
Founded Year: 1935
Market Cap: $10.77B
Total Employees: 37-736
Headquarter: Petah Tikva- Israel
Stock Exchange: NYSE
Teva is a global pharmaceutical company which is specialized in generic medicines. Teva is the world’s leading generic drug producer. In October 2020- Teva launched first generic versions of HIV-1 treatment Truvada and Atripla. In 2020- Teva has generated revenue of $9.31B from its generic segment.
Generic Segment Revenue: $9.46B
Founded Year: 2003
Market Cap: $208.86B
Total Employees: 26-500
Headquarter: Holzkirchen- Germany
Stock Exchange: NA
Sandoz is a leading pharmaceutical company that mainly focuses on generics and Biosimilars. The company is organized globally into three divisions Retail Generics- Anti-Infectives- and Biopharmaceuticals. In August 2020- Sandoz launched Ciprofloxacin and Dexamethasone otic suspension for the treatment of middle and outer ear canal bacterial infections. In 2020- Sandoz generated revenue of $9.46B from its generic segment.
- For Viatris- only the biosimilar revenue was considered. Complex biosimilar and generics are not considered
- In the annual report of Fresenius Kabi- the revenue was mentioned in percentage- so we calculated it as per the requirement
- Source: Company annual reports- SEC filings- press releases- and company websites
- Market Cap source: Google finance (as of 28th Oct 2021)
- All revenues are reported in USD
Related Post: Top 20 Generics Pharma Companies Based On 2019 Revenue
